- €1.07bn
- €1.43bn
- €1.12bn
- 62
- 59
- 18
- 40
Annual income statement for Jenoptik AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 615 | 751 | 981 | 1,066 | 1,116 |
| Cost of Revenue | |||||
| Gross Profit | 225 | 257 | 354 | 377 | 388 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 568 | 643 | 879 | 940 | 969 |
| Operating Profit | 47.7 | 108 | 102 | 126 | 147 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 42.3 | 103 | 96 | 111 | 130 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 34 | 92.9 | 63.9 | 73.8 | 92.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 41.8 | 82 | 55.1 | 72.5 | 92.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 41.8 | 82 | 55.1 | 72.5 | 92.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.714 | 1.71 | 1.37 | 1.54 | 1.79 |
| Dividends per Share |